■ Huons said on the 3rd it will provide free lending of the receiver for the continuous glucose monitor "Dexcom G7," which test-takers with type 1 diabetes can bring into College Scholastic Ability Test sites. Dexcom G7 is a continuous glucose monitor that measures glucose levels in interstitial fluid via a sensor attached to the skin and allows users to check glucose in real time through a smartphone or a dedicated receiver.
■ Seoul National University Hospital Healthcare AI Institute said on the 3rd it signed a transfer contract for cardiac arrest prediction artificial intelligence (AI) technology with the medical AI corporations HolmesAI. The institute's cardiac arrest prediction AI technology will be mounted on HolmesAI's AI platform to push forward with technology advancement and commercialization. The two institutions will also jointly pursue commercialization of real-time AI monitoring technology that can predict and respond to patients' acute cardiac arrest. The AI technology developed at Seoul National University Hospital can predict the likelihood of cardiac arrest using only single-channel electrocardiogram (ECG) data. Using heart rate variability (HRV) indices to quantitatively reflect changes in the autonomic nervous system, it significantly improved analytical performance over conventional simple statistics-based prediction models.
■ Celltrion said on the 3rd it obtained additional approval from the U.S. Food and Drug Administration (FDA) for the 10 mg/0.1 mL (hereafter 10 mg) dosage form of the autoimmune disease treatment "Yuflyma." Yuflyma, a high-concentration Humira biosimilar, halves the administered volume compared with the low-concentration version and removes citrate (citric acid), which can cause pain. A company official said, "We have secured the full lineup of high-concentration products in the market," and added, "With customized prescriptions now possible for diverse patient cases, we will do our best to expand U.S. market share based on our product competitiveness."
■ Curocell said on the 3rd it signed a commercial supply contract for viral vectors with ProBio, a cell and gene therapy (CGT) specialty contract development and manufacturing (CDMO) corporations. The company said that with this contract, it has secured a foundation to stably procure viral vectors for more than 1,000 patients annually. The company's CAR-T Therapy "LIMCAUTO" is undergoing item approval review by the Ministry of Food and Drug Safety. The company established a supply chain to enter the commercialization stage.
■ Lotte Biologics said on the 3rd it will participate in "World ADC San Diego 2025," held in San Diego. This is the world's largest event in the Antibody-Drug Conjugate (ADC) field. Jang Geon-hee, head of technology development, will give a presentation on the theme "Accelerating bioconjugate development & manufacturing with LOTTE BIOLOGICS' ADC platform," and plans to promote Lotte Biologics' ADC CDMO service competitiveness.
■ GeoYoung said on the 3rd that after fully entering the rare-disease drug distribution business in 2023, it expanded the number of items supplied from 80 in the first year of supply to 122 in two years, up 52.2%. Supply volume is also steadily increasing. The supply volume of rare-disease drugs surged 87.2% from 89,582 in 2023 to 186,398 in 2024. The supply volume over one year was 195,429, up 16.3% from 168,077 in the same period a year earlier.
■ Park Jae-yong, a professor of pulmonology at Kyungpook National University Chilgok Hospital, and Jung Man-pyo, a professor of pulmonology at Samsung Medical Center, received the 47th Yuhan Tuberculosis and Respiratory Science Award. Established in 1979 by Yuhan Corporation and the Korean Academy of Tuberculosis and Respiratory Diseases, the award is given annually to a medical scientist with outstanding contributions to advances in this field.
■ Hanmi Pharmaceutical said on the 3rd it launched a tailored antipyretic-analgesic for infants and children, "SUSpen Kids Syrup." SUSpen Kids Syrup is an over-the-counter drug containing only acetaminophen and can be used broadly for fever and pain from colds, headaches, neuralgia, and myalgia. It can be taken from 4 months of age, with dosage adjusted by age and weight. The product comes as stick-type pouches individually packed at 6 mL each (10 pouches total) and features an apple flavor familiar to children.
■ HLB PAHRMA said on the 3rd it launched Korea's first "sugar-free liquid albumin." The new product, "Albumin Intensive Gold 329," is an upgraded version of the existing "Albumin Intensive Gold 285." It reduced sugar content to 0 g and increased the albumin complex content to 99.9% compared with the previous product.
■ Dong-A ST said on the 3rd it opened the "Happiness Car Wash" at its headquarters in Yongdu-dong, Dongdaemun-gu, Seoul. The Happiness Car Wash was established to support the self-reliance of people with disabilities, a socially vulnerable group, and to create an inclusive workplace where everyone grows together. It will also operate as an in-house welfare space that contributes to improving employee welfare at Dong-A Socio Group.